Antibody ID	ANI0DRBTO
Antibody Name	Anti-EPHA2 mAb
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG1-kappa
Antigen Name	Ephrin type-A receptor 2 (EPHA2)					Antigen Info
Click to Show/Hide the Sequence Information of This Antibody

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.4 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.6 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.7 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.1 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.2 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.4 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3.6 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.2 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.2 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4.7 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5.6 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	6.5 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	7.3 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	7.9 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	9.1 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	10.3 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	10.4 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	12.2 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	13.2 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	14.4 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	52.5 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	63.5 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	307 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 10000 nM	Positive EPHA2 expression (EPHA2+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the THP1-DualTM cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Childhood acute monocytic leukemia	THP1-Dual cells		CVCL_X599

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	11 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.3 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	10 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.3 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	13 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.01 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.04 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.05 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	8 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.02 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	26 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	3 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	12 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	12 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	4 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	29 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	29 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	7 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	20 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the L540cy cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Hodgkin's disease	L540cy cells		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the Karpas-299 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	ALK-positive anaplastic large cell lymphoma	Karpas-299 cells		CVCL_1324
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MOLM-13 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Adult acute myeloid leukemia	MOLM-13 cells		CVCL_2119
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the SU-DHL-4 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Diffuse large B-cell lymphoma	SU-DHL-4 cells		CVCL_0539
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the MDA-MB-231 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Breast adenocarcinoma	MDA-MB-231 cells		CVCL_0062
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the Ls174T cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the BxPC3 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Pancreatic ductal adenocarcinoma	BxPC-3 cells		CVCL_0186
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the A2058 cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 1000 ng/mL	Positive EPHA2 expression (EPHA2+++/++); Negative CD30 expression (CD30-)
Method Description	Potency of compounds and ADCs was evaluated using the 786-O cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Renal cell carcinoma	786-O cells		CVCL_1051
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells (Brentuximab vedotin resistance). Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells (Brentuximab vedotin resistant)		CVCL_1170
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	> 4 pg/mL	Positive EPHA2 expression (EPHA2+++/++); Positive CD30 expression (CD30+++/++)
Method Description	Potency of compounds and ADCs was evaluated using the DEL cells. Cells were plated in a 96-well flat bottom tissue culture-treated clear polystyrene plate at ~100,000 cells per well in 200 uL with the indicated concentration of the compound or ADC.
In Vitro Model	Anaplastic large cell lymphoma	DEL cells		CVCL_1170

Ref 1	Immunomodulatory antibody-drug conjugates; 2022-07-21.